We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
- Authors
Requena, Silvia; Treviño, Ana; Cabezas, Teresa; Garcia-Delgado, Rosa; José Amengual, María; Belén Lozano, Ana; Peñaranda, María; Manuel Fernández, Juan; Soriano, Vicente; de Mendoza, Carmen; Amengual, María José; Lozano, Ana Belén; Fernández, Juan Manuel; Spanish HIV-2 Study Group
- Abstract
<bold>Background: </bold>A broader extent of amino acid substitutions in the integrase of HIV-2 compared with HIV-1 might enable greater cross-resistance between raltegravir and dolutegravir in HIV-2 infection. Few studies have examined the virological response to dolutegravir in HIV-2 patients that failed raltegravir.<bold>Methods: </bold>All patients recorded in the HIV-2 Spanish cohort were examined. The integrase coding region was sequenced in viraemic patients. Changes associated with resistance to raltegravir and dolutegravir in HIV-1 were recorded.<bold>Results: </bold>From 319 HIV-2-infected patients recorded in the HIV-2 Spanish cohort, 53 integrase sequences from 30 individuals were obtained (20 raltegravir naive and 10 raltegravir experienced). Only one secondary mutation (E138A) was found in one of the 20 raltegravir-naive HIV-2 patients. For raltegravir-experienced individuals, the resistance mutation profile in 9 of 10 viraemic patients was as follows: N155H + A153G/S (four); Y143G + A153S (two); Q148R + G140A/S (two); and Y143C + Q91R (one). Of note, all patients with Y143G and N155H developed a rare non-polymorphic mutation at codon 153. Rescue therapy with dolutegravir was given to 5 of these 10 patients. After >6 months on dolutegravir therapy, three patients with baseline N155H experienced viral rebound. In two of them N155H was replaced by Q148K/R and in another by G118R.<bold>Conclusions: </bold>A wide repertoire of resistance mutations in the integrase gene occur in HIV-2-infected patients failing on raltegravir. Although dolutegravir may allow successful rescue in most HIV-2 raltegravir failures, we report and characterize three cases of dolutegravir resistance in HIV-2 patients, emerging variants Q148K and Q148R and a novel change G118R.
- Subjects
HIV-positive persons; DRUG resistance; HIV; HIV infections; THERAPEUTICS; MEDICAL care; ANTI-HIV agents; HIV integrase inhibitors; AMINO acids; DRUG resistance in microorganisms; GENETIC mutation; HETEROCYCLIC compounds; PROTEINS; RNA; TREATMENT effectiveness; VIREMIA
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2017, Vol 72, Issue 7, p2083
- ISSN
0305-7453
- Publication type
journal article
- DOI
10.1093/jac/dkx090